The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Effects of Chemical Modifications on Aggregation of Alpha-synuclein
Study Rationale: Evidence suggests that alpha-synuclein causes the death of neurons in the brains of people with Parkinson’s disease (PD) by forming clusters (or ‘aggregates’) on the surface of...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program - Therapeutics, 2023Assessing the Ability of Dapansutrile, a Selective, Oral Inhibitor of the NLRP3 Neuroinflammatory Pathway, to Mitigate Progression of Parkinson’s Disease
Study Rationale: Increasing scientific data indicate the role of neuroinflammation in the pathology of Parkinson’s disease (PD) and related alpha-synucleinopathies. Dapansutrile (lab code: OLT1177®...
-
Biomarkers to Support Therapeutic Trials Program, 2023Blood Test for Stratifying People with Parkinson’s Disease based on Extracellular Vesicles Derived from Neurons
Study Rationale: Parkinson’s disease (PD) and other synucleinopathies are diagnosed based on symptoms and clinical testing. However, these tests can be inaccurate, and postmortem analysis reveals that...
-
Biomarkers to Support Therapeutic Trials Program, 2023Analyzing the Aggregation Properties of Alpha-synuclein in Different Genetic Subtypes of Parkinson’s Disease
Study Rationale: Abnormal clumping of alpha-synuclein appears to be an important cause for the death of dopamine cells in Parkinson disease (PD). Recent studies discovered that small amounts of tiny...
-
Accelerating Biological Understanding and Therapeutic Translation for Parkinson’s Disease Program, 2023Inhibiting Programmed Cell Death to Reduce Axonal Degeneration and Brain Inflammation in Parkinson's Disease
Study Rationale: The degeneration of neuronal axons is an early pathological feature of Parkinson’s disease (PD) and an attractive target for therapeutic intervention. We have demonstrated that a...
-
Research Grant, 2023Allogeneic Bone marrow-derived Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson’s Disease: Phase 2a Double-Blind, Randomized Controlled Trial
Study Rationale: Chronic neuroinflammation plays a critical role in the development and progression of Parkinson’s disease (PD). Neuroinflammation damages the brain microenvironment, disrupts the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.